Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amphotericin B

FDA-approved product (ointment, topical), marketed as Abelcet, Ambisome, Amphotec and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amphotericin B
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Cryptococcal meningitis
  • Cryptococcosis
  • Fungal infectious disease
  • Histoplasmosis
  • Infection
  • Mucormycosis
  • Sporotrichosis
  • Visceral Leishmaniasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antibiotics
FDA pharmacologic class
Lipid-based Polyene Antifungal; Polyene Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB04; WHO ATC A07AA07; WHO ATC G01AA03; WHO ATC J02AA01; FDA class Lipid-based Polyene Antifungal; FDA class Polyene Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Open Amphotericin B in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amphotericin B with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

    NCT01303549 · start 2011-11

    Registered record
    Registry ID
    NCT01303549
    Conditions
    Liver Disease; Fungal Infection
    Interventions
    Anidulafungin; Liposomal amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-05
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Disease; Fungal Infection
    InterventionAnidulafungin; Liposomal amphotericin B
    PhasePhase 4
    Registry statusCompleted

  • Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

    NCT02366884 · start 2011-07-26

    Registered record
    Registry ID
    NCT02366884
    Conditions
    Neoplasms
    Interventions
    Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07-26
    Completion
    2023-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

    NCT01310738 · start 2011-02

    Registered record
    Registry ID
    NCT01310738
    Conditions
    Visceral Leishmaniasis
    Interventions
    Antimoniate of N-methylglucamine; amphotericin B deoxycholate; Liposomal amphotericin B; Liposomal amphotericin B; Antimoniate of N-methylglucamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2015-02
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAntimoniate of N-methylglucamine; amphotericin B deoxycholate; Liposomal amphotericin B; Liposomal amphotericin B +1 more
    PhasePhase 4
    Registry statusTerminated

  • To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

    NCT00876824 · start 2009-07

    Registered record
    Registry ID
    NCT00876824
    Conditions
    Leishmaniasis, Visceral
    Interventions
    Amphotericin B Lipid emulsion; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Visceral
    InterventionAmphotericin B Lipid emulsion; Liposomal Amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • Antifungal Prophylaxis in Pediatric Acute Leukemia

    NCT00624143 · start 2008-02

    Registered record
    Registry ID
    NCT00624143
    Conditions
    Pediatric Acute Leukemia Induction
    Interventions
    ORAL VORICONAZOLE and IV Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Acute Leukemia Induction
    InterventionORAL VORICONAZOLE and IV Amphotericin B
    PhasePhase 3
    Registry statusUnknown

  • Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

    NCT00634166 · start 2007-09

    Registered record
    Registry ID
    NCT00634166
    Conditions
    Burns
    Interventions
    Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2014-04
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionSulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    PhasePhase 4
    Registry statusTerminated

  • CRITIC - Treatment of Candidemia and Invasive Candidiasis

    NCT00670657 · start 2007-05

    Registered record
    Registry ID
    NCT00670657
    Conditions
    Candidemia; Invasive Candidiasis
    Interventions
    AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia; Invasive Candidiasis
    InterventionAmBisome
    PhasePhase 4
    Registry statusCompleted

  • A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar

    NCT00497601 · start 2007-02

    Registered record
    Registry ID
    NCT00497601
    Conditions
    Visceral Leishmaniasis
    Interventions
    Amphotericin B fat emulsion in visceral leishmaniasis; Amphotericin B fat emulsion; Amphotericin B in fat emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2008-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAmphotericin B fat emulsion in visceral leishmaniasis; Amphotericin B fat emulsion; Amphotericin B in fat emulsion
    PhasePhase 2
    Registry statusCompleted

  • Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

    NCT01656382 · start 2007-01

    Registered record
    Registry ID
    NCT01656382
    Conditions
    Invasive Cryptococcosis
    Interventions
    ABLC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-01
    Completion
    2010-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Cryptococcosis
    InterventionABLC
    PhasePhase 4
    Registry statusWithdrawn

  • Amphotericin B Suspension in Refractory Chronic Sinusitis

    NCT00425620 · start 2006-12

    Registered record
    Registry ID
    NCT00425620
    Conditions
    Chronic Sinusitis
    Interventions
    SinuNase
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2007-10
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Sinusitis
    InterventionSinuNase
    PhasePhase 3
    Registry statusCompleted

  • Antimicrobial PK in Infants With Suspected or Confirmed Infection

    NCT00491426 · start 2006-01

    Registered record
    Registry ID
    NCT00491426
    Conditions
    Infection
    Interventions
    Ampicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir; Amphotericin B; Ambisome; Anidulafungin; Caspofungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2010-11
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionAmpicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Ambisome in Liver Transplant Patients

    NCT00161356 · start 2005-09

    Registered record
    Registry ID
    NCT00161356
    Conditions
    Liver Transplantation
    Interventions
    Ambisome; Liver Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2005-09
    Completion
    2007-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionAmbisome; Liver Biopsy
    PhasePhase 4
    Registry statusTerminated

  • Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

    NCT00216346 · start 2003-06

    Registered record
    Registry ID
    NCT00216346
    Conditions
    Visceral Leishmaniasis
    Interventions
    Paromomycin sulfate; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-06
    Completion
    2004-11
    Enrolment
    667

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionParomomycin sulfate; Amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

    NCT00158730 · start 2003-04

    Registered record
    Registry ID
    NCT00158730
    Conditions
    Invasive Aspergillosis; Other Fungal Infections
    Interventions
    AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-04
    Completion
    2005-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis; Other Fungal Infections
    InterventionAmBisome
    PhasePhase 3
    Registry statusCompleted

  • Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

    NCT00047827 · start 2002-12

    Registered record
    Registry ID
    NCT00047827
    Conditions
    Aspergillosis
    Interventions
    Micafungin; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2002-12
    Completion
    2003-02
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    InterventionMicafungin; Liposomal Amphotericin B
    PhasePhase 2
    Registry statusTerminated